Clinical Trial Update: Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 [Phase 2]

View source ↗

Summary

Phase 2 continuation trial evaluating tolerability and activity of FK228 in patients who completed prior FK228 study (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Neoplasms
• Renal Cell Carcinoma

Drugs mentioned

• FK228

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Renal Cell, Prostatic Neoplasms | Phase 2 | Status: COMPLETED